M. A. Sofia and D. T. Rubin, The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions, Dig Dis Sci, vol.62, pp.833-875, 2017.

C. J. Williams, L. Peyrin-biroulet, and A. C. Ford, Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease, Aliment Pharmacol Ther, vol.39, pp.447-58, 2014.

M. Lemaitre, Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease, JAMA, vol.318, pp.1679-86, 2017.

E. Louis, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, vol.142, pp.63-70, 2012.

M. Bortlik, Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation, Scand J Gastroenterol, vol.51, pp.196-202, 2016.

C. Reenaers, Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission, Clin Gastroenterol Hepatol, vol.16, p.2, 2018.

, Accepted Article

G. Fiorino, Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study, Clin Gastroenterol Hepatol, vol.14, p.1, 2016.

T. Bejan-angoulvant, Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis, Arthritis Rheumatol, vol.69, pp.108-121, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01980809

A. Amiot, Therapeutic drug monitoring is predictive of loss of response after deescalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission, Clin Res Hepatol Gastroenterol, vol.40, pp.90-98, 2016.

C. Lucidarme, Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring, Aliment Pharmacol Ther, vol.49, pp.147-54, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01998041

N. Vande-casteele, Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease, Gastroenterology, vol.148, pp.1320-1329, 2015.

A. Petitcollin, Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study, Inflamm Bowel Dis, vol.24, pp.1745-54, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01821736

J. F. Brandse, A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease, Inflamm Bowel Dis, vol.23, pp.650-60, 2017.

D. J. Buurman, J. M. Maurer, R. J. Keizer, J. G. Kosterink, and G. Dijkstra, Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice, Aliment Pharmacol Ther, vol.42, pp.529-568, 2015.

A. Aubourg, L. Picon, T. Lecomte, T. Bejan-angoulvant, G. Paintaud et al., A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease, Eur J Clin Pharmacol, vol.71, pp.1541-1543, 2015.

A. A. Fasanmade, Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis, Eur J Clin Pharmacol, vol.65, pp.1211-1239, 2009.

D. Ternant, Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis, Br J Clin Pharmacol, vol.79, pp.286-97, 2015.

L. Peyrin-biroulet, Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions, Clin Gastroenterol Hepatol, vol.14, pp.348-54, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01668509

C. Passot, The underlying inflammatory chronic disease influences infliximab pharmacokinetics, MAbs, vol.8, pp.1407-1423, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01980816

D. Ternant, Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, Br J Clin Pharmacol, vol.78, pp.118-146, 2014.